Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Saved in:
| Title: | Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. |
|---|---|
| Authors: | Bissonnette, R.1 rbissonnette@innovaderm.ca, Luger, T.2, Thaçi, D.3, Toth, D.4, Messina, I.5, You, R.6, Guana, A.5, Fox, T.7, Papavassilis, C.7, Gilloteau, I.7, Mrowietz, U.8 |
| Source: | British Journal of Dermatology. Oct2017, Vol. 177 Issue 4, p1033-1042. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 00070963 |
|---|---|
| DOI: | 10.1111/bjd.15706 |
